Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone

Rheumatology

Volumn 42, Issue 8, 2003, Pages 989-994

  Fox, R I ^e   Morgan, S L ^a   Smith, H T ^b   Robbins, B A ^c   Choc, M G ^d   Baggott, J E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAYER CORPORATION   (United States)

^d SANOFI   (France)

^e SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

7 Hydroxymethotrexate; Cyclosporin A; Methotrexate; Pharmacokinetics

Indexed keywords

7 HYDROXYMETHOTREXATE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DRUG METABOLITE; FLURBIPROFEN; GOLD DERIVATIVE; KETOPROFEN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENTIATION; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED;

EID: 0141615878     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg277     Document Type: Article

References (23)

1. O'Dell JR, Scott DL. Rheumatoid arthritis: New developments in the use of existing therapies. Rheumatology 1999;38:24-6.
2. van de Putte LBA, Kroot EJA, van Riel PLCM. Management of refractory rheumatoid arthritis. Rheumatology 1999;38:32-4.
3. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. Methotrexate-cyclosporine combination study group. N Engl J Med 1995;33:137-41.
4. Stein CM, Pincus T. Combination treatment of rheumatoid arthritis with cyclosporine and methotrexate. Clin Exp Rheumatol 1999;17:S47-S52.
5. Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacol 1996;30:194-210.
6. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;35:409-12.
7. Fabre G, Seither R, Goldman ID. Hydroxylation of 4-amino-antifolates by partially purified aldehyde oxidase from rabbit liver. Biochem Pharmacol 1986;35:1325-30.
8. Al-Salmy HS. Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 2001;51:249-53.
9. Sonneveld P, Schultz FW, Nooter K, Hählen K. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol 1986;18:111-6.
10. Baggott JE, Morgan SL, Koopman WJ. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 1998;41:1407-10.
11. Borel JF, Bauman G, Chapman I et al. In vivo pharmacological effects of cyclosporine and some analogues. Adv Pharmacol 1996;35:115-246.
12. Mueller EA, Niese D, Mellein B. Cyclosporine microemulsion formation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships. Transplant Proc 1998;30:1694-6.
13. Cranney A, Tugwell P. The use of Neoral in rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:479-88.
14. Choc M. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune®. Int J Dermatol 1997;36:1-6.
15. Cavarape A, Endlich K, Feletto F, Parekh N, Bartoli E, Steinhausen M. Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats. Kidney Int 1998;53:963-9.
16. Furlanut M, Baraldo M, Galla F, Marzocchi V, Pea F. Cyclosporine nephrotoxicity in relation to its metabolism in psoriasis. Pharmacol Res 1996;33:349-52.
17. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Yocum DE, Torley H. Cyclosporine in rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:835-44.
19. Lee YJ, Chan KK. Metabolic interaction between methotrexate and 4′-(9-acridinylamino) methanesulfon-M-anisidide-44. in the rabbit. Cancer Res 1988;48:5106-11.
20. Egan LJ, Tremaine WJ, Mays CD, Lipsky JJ, Sandborn WJ. Clinical outcome and pharmacokinetics after addition of low dose cyclosporine to methotrexate: A case study of 5 patients with treatment resistant inflammatory bowel disease. Inflamm Bowel Dis 2000;6:286-9.
21. Fabre J, Fabre G, Cano JP. 7-Hydroxymethotrexate cytotoxicity and selectivity in human Burkitt's lymphoma cell lines versus human granulocytic progenitor cells: rescue by folinic acid and nucleosides. Eur J Cancer Clin Oncol 1986;22:1247-54.
22. Sasaki K, Hosoya R, Wang Y-M, Raulston GL. Formation and disposition of 7-hydroxymethotrexate in rabbits. Biochem Pharmacol 1983;32:503-7.
23. Seidemann P, Muller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993;20:1126-8.